De-escalated Dual Antiplatelet Therapy — Competitive Intelligence Brief

De-escalated Dual Antiplatelet Therapy (De-escalated Dual Antiplatelet Therapy) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet therapy regimen. Area: Cardiovascular.

marketed Antiplatelet therapy regimen Cardiovascular Small molecule

Target snapshot

De-escalated Dual Antiplatelet Therapy (De-escalated Dual Antiplatelet Therapy) — China National Center for Cardiovascular Diseases. De-escalated dual antiplatelet therapy reduces the duration or intensity of combined antiplatelet treatment to minimize bleeding risk while maintaining thrombotic protection.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
De-escalated Dual Antiplatelet Therapy TARGET	De-escalated Dual Antiplatelet Therapy	China National Center for Cardiovascular Diseases	marketed	Antiplatelet therapy regimen
short postimplantation dual antiplatelet therapy	short postimplantation dual antiplatelet therapy	National Institute of Cardiology, Warsaw, Poland	marketed	Antiplatelet therapy regimen
Long DAPT	Long DAPT	Federico II University	phase 3	Antiplatelet therapy regimen	P2Y12 receptor and cyclooxygenase (COX)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet therapy regimen class)

1. China National Center for Cardiovascular Diseases · 1 drug in this class
2. Federico II University · 1 drug in this class
3. National Institute of Cardiology, Warsaw, Poland · 1 drug in this class